ADVERTISEMENT
ADVERTISEMENT
This author has not written his bio yet.
But we are proud to say that Uta Mommert contributed 234 entries already.
Genentech, Roches US subsidiary, is ending its decades-long collaboration with AC Immune SA after disappointing study results. It has handed the global rights to Crenezumab and Semorinemab back to the Lausanne-based biotech.
In an effort to address the global health threat of antimicrobial resistance (AMR), Innovate UK, LifeArc, and Medicines Discovery Catapult have jointly launched the PACE (Pathways to Antimicrobial Clinical Efficacy) initiative. With £30m (around €34,5m) in funding, PACE aims to support early-stage innovations aimed at countering AMR.
Orano Med SAS and Orbit Discovery Ltd announced a collaboration to develop Peptide Receptor Radionuclide Therapies for cancer cells and develop novel radiopharmaceuticals.
Non-profit foundation BioInnovation Institute (BII) has unveiled its latest commitment to driving innovation and growth within the life science sector. Six promising companies will receive crucial financial support through BIIs Venture House programme.
The UK is making €15m investment in its biopharmaceutical manufacturing industry via its national innovation agency Innovate UK. It is part of the country’s larger push to support the domestic Life Sciences.
British CDMO Oxford Biomedica plc announces the expansion of its License and Supply Agreement with cell therapy specialist Cabaletta Bio, Inc. The new agreements adds CD19 as a new target – it originally covered Cabaletta Bios lead product, DSG3-CAART.
Milan-based biotech incubator Golgi Neurosciences is teaming up with Danish biopharma Breye Therapeutics to develop the P2X7 receptor antagonist programme for the treatment of retinal disorders.
Italian pharma company Recordati is putting €750m on the table to acquire UK-based specialty pharmaceutical company EUSA Pharma.
Sanofi is strengthening its vaccine business by acquiring an Austrian company. The French pharma group is taking over skin disease specialist Origrimm Biotechnology.
Quell Therapeutics has raised a whopping US$156m from a prestigious investor group in an oversubscribed Series B financing. With the funds, the British biotech wants to hasten its CAR-Treg cell therapy candidate on its way to the clinic.